Today: 28 February 2026
Subscribe
Browse Category

Pharmaceuticals 15 February 2026 - 28 February 2026

Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Eli Lilly shares rose 2.93% to $1,051.99 Friday, outperforming a falling market. Full results from a diabetes trial showed Lilly’s oral drug orforglipron caused more nausea and discontinuations than Novo Nordisk’s Rybelsus, but produced greater A1C and weight reduction. The 52-week study involved 1,698 patients. Novo plans to cut U.S. list prices for Ozempic and Wegovy by up to 50% starting in 2027.
28 February 2026
···
GSK share price today: stock edges up after Japan and China reviews, plus $950 million 35Pharma deal

GSK share price today: stock edges up after Japan and China reviews, plus $950 million 35Pharma deal

GSK shares rose 0.74% to 2,183 pence by 0855 GMT after Japan and China accepted regulatory filings for two experimental liver-disease drugs. The company also agreed to buy Canada’s 35Pharma for $950 million, adding a pulmonary hypertension asset. GSK closed down 2.12% the previous session. Investors await first-quarter results on April 29.
27 February 2026
··
Celldex Therapeutics (CLDX) stock slips in premarket after 24% rally on Phase 3 barzolvolimab milestone

Celldex Therapeutics (CLDX) stock slips in premarket after 24% rally on Phase 3 barzolvolimab milestone

Celldex Therapeutics shares fell about 4% to $29.58 in premarket trading Thursday, after surging 24% the previous session. The company completed enrollment in two global Phase 3 barzolvolimab studies for chronic spontaneous urticaria six months ahead of schedule. Topline data are expected in Q4 2026, with a U.S. BLA filing planned for 2027. Celldex ended 2025 with $518.6 million in cash and posted a full-year net loss of $258.8 million.
26 February 2026
··
Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus

Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus

Eli Lilly shares fell 1.28% to $1,028.83 Wednesday after the FDA cleared a four-dose Zepbound KwikPen for obesity treatment. Novo Nordisk’s CagriSema showed less weight loss than Lilly’s tirzepatide in a head-to-head trial. Analysts called the gap significant for investors. Lilly said the new KwikPen will cost $299 per month at the 2.5 mg dose.
26 February 2026
···
GSK shares nudge up on $950 mln 35Pharma deal as dealmaking picks up

GSK shares nudge up on $950 mln 35Pharma deal as dealmaking picks up

GSK agreed to buy Canada’s 35Pharma for $950 million in cash, adding experimental pulmonary hypertension drug HS235 to its pipeline. GSK shares rose 0.1% to 2,204 pence in early London trading. The deal is subject to regulatory approval in the U.S. and Canada. GSK also reported buying back 462,000 shares as part of its ongoing share repurchase program.
25 February 2026
·
Dianthus Therapeutics (DNTH) stock rises ahead of TD Cowen conference; what investors watch next

Dianthus Therapeutics (DNTH) stock rises ahead of TD Cowen conference; what investors watch next

Dianthus Therapeutics shares rose 6.3% to $52.68 Monday ahead of CEO Marino Garcia’s scheduled fireside chat at TD Cowen’s health care conference on March 3. Volume reached about 944,000 shares. Investors are watching for updates on the company’s autoimmune pipeline and trial timelines. The event will be webcast and include one-on-one investor meetings.
24 February 2026
··
Novo Nordisk stock slips again as CagriSema miss drives forecast cuts and puts next catalysts in focus

Novo Nordisk stock slips again as CagriSema miss drives forecast cuts and puts next catalysts in focus

Novo Nordisk shares fell 2.5% to 245.1 Danish crowns Tuesday after its CagriSema obesity drug failed to match Eli Lilly’s tirzepatide in a Phase 3 trial. Barclays cut its peak sales forecast for CagriSema to $2 billion from $12 billion. Novo also reported mid-stage China trial results for its “triple G” obesity drug UBT251, showing up to 19.7% weight loss after 24 weeks.
24 February 2026
··
Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly shares climbed nearly 5% late Monday after Novo Nordisk reported its obesity drug CagriSema underperformed Lilly’s Zepbound in a head-to-head trial. Novo’s U.S.-listed shares dropped over 16%. CagriSema showed 23% weight loss after 84 weeks, compared to 25.5% for Zepbound. The trial failed to prove CagriSema was not worse than tirzepatide on weight loss.
23 February 2026
····
Organon stock jumps in premarket after MIUDELLA licensing deal, with 10-K filing in focus

Organon stock jumps in premarket after MIUDELLA licensing deal, with 10-K filing in focus

Organon shares jumped 7.8% to $8.10 in premarket trading Monday after the company announced a global licensing deal for MIUDELLA, a hormone-free copper IUD from Sebela Pharmaceuticals. Organon agreed to pay $27.5 million upfront and up to $505 million in sales-based milestones, pending antitrust and FDA approvals. The company’s dividend record date is Monday, with payment set for March 12.
23 February 2026
··
Vanda Pharmaceuticals stock jumps premarket after FDA clears Bysanti — what to watch at the open

Vanda Pharmaceuticals stock jumps premarket after FDA clears Bysanti — what to watch at the open

Vanda Pharmaceuticals shares jumped 33% to $7.68 in premarket trading Monday after the FDA approved its new antipsychotic pill, Bysanti, late Friday. The drug, milsaperidone, is bioequivalent to Vanda’s existing Fanapt and will be available commercially in the third quarter of 2026. Traders are watching whether the rally holds at the open and how Bysanti will compete in a crowded market.
23 February 2026
··
Johnson & Johnson stock price: JNJ heads into Monday as Tremfya data lands and dividend date nears

Johnson & Johnson stock price: JNJ heads into Monday as Tremfya data lands and dividend date nears

Johnson & Johnson shares closed at $242.49 on Friday, down 1.8%. The company released new three-year Tremfya data in ulcerative colitis over the weekend. J&J stock goes ex-dividend Feb. 24, with a $1.30-per-share payout set for March 10. A potential $20 billion sale of its DePuy Synthes orthopedics unit remains under discussion.
22 February 2026
···
Johnson & Johnson stock price: JNJ heads into Monday with DePuy sale talk and Tremfya data

Johnson & Johnson stock price: JNJ heads into Monday with DePuy sale talk and Tremfya data

Johnson & Johnson shares fell 1.8% to $242.49 Friday after Reuters reported the company is preparing a potential $20 billion sale of its DePuy Synthes orthopedics unit. J&J released new long-term data for Tremfya in ulcerative colitis, showing 80.8% remission at week 140. The company did not comment on the reported DePuy sale. Investors await management updates in March and April.
21 February 2026
··
GSK share price slips as Arexvy RSV data lands and stock goes ex-dividend

GSK share price slips as Arexvy RSV data lands and stock goes ex-dividend

GSK shares fell 0.4% in early London trading Thursday after the company released new real-world data on its RSV vaccine Arexvy and the stock went ex-dividend. A U.S. study linked Arexvy to reduced RSV-related hospitalisations and lower rates of major cardiovascular events in adults over 60. GSK also bought back 420,000 shares on Feb. 17. Investors await further RSV data and updates on dividends.
19 February 2026
····
Why CSL’s share price is moving: Lilly clazakizumab deal, buyback pace and the next dividend date

Why CSL’s share price is moving: Lilly clazakizumab deal, buyback pace and the next dividend date

CSL shares closed up 0.95% at A$154.19 in Sydney, marking a second consecutive gain after announcing a US$100 million licensing deal with Eli Lilly for clazakizumab. ASX filings showed CSL continued its share buyback and a director increased holdings. The stock remains about 15% below early-February levels. CEO Paul McKenzie is set to retire, with Gordon Naylor named interim chief.
19 February 2026
···
Why GSK stock is moving today: Exdensur EU nod and a fresh buyback

Why GSK stock is moving today: Exdensur EU nod and a fresh buyback

GSK shares rose 1.1% to 2,263 pence after the European Commission approved its twice-yearly asthma drug Exdensur and the company launched a new tranche of share buybacks. GSK will repurchase up to £0.45 billion in shares by April 24. The company also reported new real-world data showing its RSV vaccine Arexvy was 75.6% effective against RSV-related hospitalisation in adults over 60.
18 February 2026
··
Eli Lilly stock in focus as Retevmo lung cancer trial meets endpoint, with trading back Tuesday

Eli Lilly stock in focus as Retevmo lung cancer trial meets endpoint, with trading back Tuesday

Eli Lilly reported its cancer drug Retevmo beat placebo on event-free survival in a Phase 3 trial for early-stage RET fusion-positive non-small cell lung cancer. U.S. markets are closed for Presidents Day, delaying any stock reaction until Tuesday. Lilly shares last closed at $1,040, up 0.2% Friday. Full trial data will be presented at a future medical meeting.
16 February 2026
··
AbbVie stock ends higher Friday; what traders watch for ABBV after the Presidents Day break

AbbVie stock ends higher Friday; what traders watch for ABBV after the Presidents Day break

AbbVie shares closed up 1.8% at $231.50 Friday, outpacing Johnson & Johnson. U.S. markets will be closed Monday for Presidents Day, with trading set to resume Tuesday. Investors are weighing AbbVie’s drug-pricing moves and pipeline as the company shifts away from Humira after patent loss. Trading volume topped its recent average, with the stock about 5% below its 52-week high.
15 February 2026
··
Healthcare stocks head into Presidents Day break after Dexcom, Moderna lift XLV

Healthcare stocks head into Presidents Day break after Dexcom, Moderna lift XLV

The Health Care Select Sector SPDR Fund (XLV) rose 1.1% to $157.67 Friday, led by Dexcom’s 7.6% jump and Moderna’s 5.3% gain after earnings. Dexcom beat Q4 estimates and reiterated its 2026 outlook, while Moderna forecast up to 10% revenue growth, citing overseas markets. Broader markets saw tech lag as inflation data cooled. U.S. exchanges close Monday for Presidents Day.
15 February 2026
··
1 2 3 … 37
Go toTop